ArticleScience translational medicine2026
Tissue origins and immune correlates of viral rebound in SIV-infected rhesus macaques after ART discontinuation.
Article in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
16 authors.
Funding
Abstract
Most persons living with HIV-1 who discontinue antiretroviral therapy (ART) demonstrate viral rebound, but the tissue-level events that lead to rebound viremia remain poorly understood. Here, we report the origin, dynamics, and correlates of viral rebound in 16 rhesus macaques (RMs) infected with molecularly barcoded SIVmac239M, treated with ART for 70 weeks, and necropsied on day 12 after ART discontinuation. Barcode analysis of plasma during daily post-ART sampling identified 1 to 38 rebounding viral lineages per animal, with a mean of 2.4 lineages contributing to initial rebound viremia. Analysis of barcode viral RNA expression in tissues revealed presumptive anatomic origin sites for 56 of 175 rebounding viral lineages, with enrichment in the gastrointestinal (GI) tract and GI-associated lymph nodes by mixed-effects logistic regression. Daily transcriptomic and proteomic profiling in peripheral blood after ART discontinuation showed up-regulation of pathways related to T cell signaling, cytokine responses, and cellular metabolism before detectable rebound viremia. These data show that viral rebound is initiated by oligofocal tissue expansion of a limited number of clonal lineages, followed by systemic dissemination and serial emergence of additional lineages from multiple tissues. Longer time to viral rebound was associated with metabolic, epigenetic, and immunologic signatures that suppress proviral reactivation. These findings advance our understanding of the tissue origins and host correlates of viral rebound and provide a framework for future studies examining GI-associated reservoir compartments, peripheral blood biomarker development, and host-directed strategies to prolong ART-free viral remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.